Multi-omics prediction in melanoma immunotherapy: A new brick in the wall
- PMID: 35016026
- DOI: 10.1016/j.ccell.2021.12.008
Multi-omics prediction in melanoma immunotherapy: A new brick in the wall
Abstract
In this issue of Cancer Cell, Newell et al. introduce whole-genome and methylome data to melanoma immunotherapy response analysis. Genome breaks are more frequent in resistant tumors, but the best response classifiers remain mutation burden and interferon-ɣ signature. Clinical translation will need aggregation of many such datasets.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.Cancer Cell. 2022 Jan 10;40(1):88-102.e7. doi: 10.1016/j.ccell.2021.11.012. Epub 2021 Dec 23. Cancer Cell. 2022. PMID: 34951955
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
